SaGA S,the Short and Graphic A bility Score: an alternative scoring method for the motor components of the Multiple Sclerosis Functional C omposite

Abstract

The timed performances of the 10-m timed walk (TMTW) and the nine-ho le peg test (NHPT) of 881 consecutive patients with multiple sclerosis (MS) undergoing a rehabilitation stay, were expressed as a logarithmic function of time in two subscores to form a composite score called the Short and G raphic A bility Score (SaGA S). The subscores (sS) were constructed in such a way that any interval of 0.5 unit corresponds to a change of 25% in the tests. The SaGA S was computed as the mean of four subscores: SaGAS=(2×2-TMTWsS+NHPTsS right hand+NHPTsS left hand). With the aid of a nomogram, the timed values of the tests are easily transformed into the corresponding subscores, which are then displayed graphically to facilitate follow-up over time. The correlation coefficients between the SaGA S and the two motor components of the MS Functional C omposite (MSFC) (r =0.987), the Expanded Disability Status Scale (EDSS)(r = -0.83), the Nottingham EADL Index (r =0.80) and the Rivermead Mobility Index (RMI) (r =0.90) were all statistically significant (P B-0.001), supporting the validity of the measure. SaGA S had a similar sensitivity to the RMI, but was significantly more sensitive than the EDSS in detecting changes occurring during the rehabilitation stay (14.9% versus 5.0%; P B-0.001) and over a one-year follow-up (35.3% versus 19.7%; P B-0.001). C ompared with the motor components of the MSFC, with which it shares several features, SaGA S has several advantages: it does not depend on the stratification of the study population; it does not skew the results of the NHPT towards improvement at the lower end; and it offers an independent assessment of both hands. SaGA S is a simple, intuitive, nonphysician-based measure, which could provide consistent scoring in future clinical trials.

Keywords

EDSS MSFC multiple sclerosis nine-hole peg test timed 10-m walk

Get full access to this article

View all access options for this article.

References

European Study Group on Interferon b-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon b-1b in the treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .

Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

Whitaker JN , Mc Farland HF , Thompson AJ , Hobart CH. Multiple sclerosis: assessment of disability and disability scales . J Neurol 1998; 245: 189-196 .

Rudick R , Antel J , Confavreux C , Cutter G , Ellison G , Fischer J et al. Recommendation from the National Multiple Sclerosis Society Clinical Outcome Assessment Task Force . Ann Neurol 1997; 42: 379-382 .

Cutter GR , Baier ML , Rudick RA , Cookfair DL , Fischer JS , Petkau J et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure . Brain 1999; 122: 871-882 .

Uitdehaag BMJ , Ader HJ , Roosma TJA , de Groot V , Kalkers NF , Polman CH. Multiple sclerosis functional composite: impact of reference population and interpretation of changes . Mult Scler 2002; 8: 366-371 .

Cohen JA , Fischer JS , Bolibrush DM , Jak AJ , Kniker JE , Mertz LA et al. Intrarater and interrater reliability of the functional composite measure . Neurology 2000; 54: 802-806 .

Hoogervost ELJ , Kalkers NF , van Wiesen LML , Uitdehaag BMJ , Polman CH. Differential treatment effect on measures of neurological exam, functional impairment and patient self-report . Mult Scler 2001; 7: 335-339 .

Uitdehaag BMMJ , Ader HJ , Kalkers NF , Polmann CH. Quantitative functional measure in MS: What is a reliable change? Letter to the editor . Neurology 2002; 59: 648-649 .

10.

Alusi SH , Worthington J , Glickman S , Findley LJ , Bain PG. Evaluation of three different ways of assessing tremor in multiple sclerosis . J Neurol Neurosurg Psychiatry 2000; 68: 756-760 .

11.

Goodkin DE , Rudick RA , VanderBrug Medendorp S , Daughtry MM , Schwetz KM , Fisher J et al. Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis . Ann Neurol 1995; 37: 30-40 .

12.

Wade DT. Measurement in neurological rehabilitation. Oxford: Oxford University Press , 1992.

13.

Vaney C , Blaurock H , Gattlen B , Meisels C. Assessing mobility in multiple sclerosis using the Rivermead Mobility Index and gait speed . Clin Rehab 1996; 10: 216-226 .

14.

Schwid SR , Goodmann AD , Mattson DH , Mihai C , Donhoe KM , Petrie MD. The measurement of ambulatory impairment in multiple sclerosis . Neurology 1997; 49: 1419-1424 .

15.

Schwid SR , Goodmann AD , McDermott MP , Bever CF , Cook SD.

Quantitative functional measures in MS: what is a reliable change?

Neurology 2002; 58: 1294-1296 .

16.

Collen FM , Wade DT , Robb GF , Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment . Int Disabil Stud 1991; 13: 50-54 .

17.

Fischer JS , Jak AJ , Knicker JE , Rudick RA , Cutter G. Administration and scoring manual for the multiple sclerosis functional composite (MSFC). New York: Demos , 1999.

18.

Mathiowetz V , Weber K , Kashmann N , Volland G. Adult norms for the nine-hole peg test of manual dexterity . Am J Occup Therapy 1985; 5: 24-37 .

19.

Granger CV , Hamilton BB , Sherwin FS. Guide for the use of the uniform data set for medical rehabilitation. Uniform Data System for Medical Rehabilitation Project Office, Buffalo General Hospital, New York, USA , 1986.

20.

Nouri FM , Lincoln NB. An extended activities of daily living scale for stroke patients . Clin Rehabil 1991; 1: 301-305 .

21.

Demeurisse G , Demol O , Robaye E. Motor evaluation in vascular hemiplegia . Eur Neurol 1980; 19: 382-389 .

22.

Perry J , Garett M , Gronley JAK , Mulroy SJ. classification of walking handicap in the stroke population . Stroke 1995; S26: 982-989 .

23.

Katzman R , Brown T , Fuld P , Peck A , Schechter R , Schimmel H. Validation of a short Orientation-Memory - concentration test of cognitive impairment . Am J Psychiatry 1983; 140: 734-739 .

24.

Hoogervost ELJ , Eikelenboom MJ , Uitdehaag BMJ , Polman CH. One year changes in disability in multiple sclerosis: neurological examination compared with patient self report . JNNP 2003; 74: 439-442 .

25.

Cohen JA , Cutter GR , Fisher JS , Goodman AD , Heidenreich FR , Jak AJ et al. Use of the MSFC as an outcome measure in the phase 3 clinical trial . Arch Neurol 2001; 58: 961-967 .

26.

Provinciali L , Ceravo MG , Bartolini M , Logullo F , Danni M. A multidimensional assessment of multiple sclerosis: relationship between disability domains . Acta Neurol Scand 1999; 100: 156-162 .

27.

Wiles CM , Newcombe RG , Fuller KJ , Shaw S , Furnival-Doran C , Pickersgill TP et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis . J Neurol Neurosurg Psychiatry 2001; 70: 174-179 .